ArticleFrontiers in genetics2026
The expression and clinical significance of miR-635 and miR-519d in gastric cancer patients.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression and clinical significance of miR-635 and miR-519d in patients with gastric cancer. Methods: A total of 116 patients with gastric cancer admitted between July 2018 and July 2020 were enrolled. Gastric cancer tissues and matched adjacent tissues obtained during surgery were collected. The expression levels of miR-635 and miR-519d were detected by quantitative real-time PCR (qRT-PCR). Kaplan-Meier survival curves were used to analyze the relationship between miR-635 and miR-519d expression and patient prognosis. Cox regression analysis was performed to identify prognostic factors. ROC curves were plotted to assess the predictive value of miR-635 and miR-519d for prognosis, and the prognostic model was internally validated using the Bootstrap method. Results: The expression levels of miR-635 and miR-519d differed significantly between gastric cancer tissues and adjacent tissues (P < 0.05). miR-635 and miR-519d were associated with TNM stage, degree of differentiation, lymph node metastasis, and depth of infiltration (P < 0.05). Their expression levels in the death group were significantly lower than those in the survival group (P < 0.05). The AUC of the combined detection of miR-635 and miR-519d for predicting prognosis was 0.935, which was superior to that of either marker alone (Z combination vs miR-635 = 2.321, Z combination vs miR-519d = 2.043, P < 0.05). The 3-year survival rates of patients with moderately decreased miR-635 or miR-519d expression were higher than those of patients with severely decreased expression (χ Conclusion: miR-635 and miR-519d are significantly downregulated in gastric cancer tissues and are associated with clinicopathological characteristics and prognosis. Their combined detection can effectively predict the prognosis of patients with gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.